Evidence map›Paper›PMID 32547142›Full record

ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2020

Serum CA125 Level Is Associated with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes.

Litong Yao, Yifan Zhong, Lingzi He, Yan Wang, Jingyang Wu, Jin Geng, Yun Zhou, Jiahua Zhang, Jun Chen, Zhongyan Shan and 4 more

Abstract read
In one paragraph

Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Can the level of HbABMC ophthalmology · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Litong Yao *China Medical University, Shenyang 110001, People's Republic of China.
Yifan Zhong *Department of Ophthalmology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Lingzi He *China Medical University, Shenyang 110001, People's Republic of China.
Yan Wang *Department of Radiology, General Hospital of Liaohe Oil Field, Panjin 124010, People's Republic of China.ORCID 0000-0002-6885-0701
Jingyang WuDepartment of Ophthalmology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Jin GengDepartment of Ophthalmology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Yun ZhouDepartment of Ophthalmology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Jiahua ZhangDepartment of Ophthalmology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Jun ChenDepartment of Ophthalmology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Zhongyan ShanDepartment of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Weiping TengDepartment of Endocrinology and Metabolism, Institute of Endocrinology, Liaoning Provincial Key Laboratory of Endocrine Diseases, The First Affiliated Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Yingying XuDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.ORCID 0000-0003-4924-9379
Lei ChenDepartment of Ophthalmology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.
Lei LiuDepartment of Ophthalmology, The First Hospital of China Medical University, Shenyang 110001, People's Republic of China.ORCID 0000-0003-1778-756X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate the association between serum carbohydrate antigen 125 (CA125) and the presence as well as severity of diabetes retinopathy (DR) in Chinese adult patients with type 2 diabetes.

methodsA hospital-based cross-sectional study was conducted from February 2012 to November 2018. DR was assessed using Early Treatment Diabetic Retinopathy Study criteria. Vision-threatening DR (VTDR) was diagnosed if subjects had severe non-proliferative DR (NPDR), proliferative DR (PDR), or clinically significant macular edema (CSME). Multivariate logistic regression models were applied to explore the associations.

resultsAmong the 2696 participants, the overall prevalence of DR was 25.1%, of which the prevalence of mild NPDR, moderate NPDR, and VTDR was 10.8%, 4.5%, and 9.9%, respectively. Serum CA125 level was significantly higher in participants with DR and increased with the severity of DR (

conclusionIn this study, serum CA125 level was associated with the presence and severity of DR in Chinese patients with type 2 diabetes. Further prospective studies should be warranted to validate the feasible role of CA125 as well as other biomarkers.

Indexed as

associationCA125diabetes retinopathytumor biomarkertype 2 diabetes

Identifiers

PMID32547142
PMCPMC7250309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.